Works matching AU Davies, Melanie J.

Results: 301
    1
    2

    Uptake of self-management education programmes for people with type 2 diabetes in primary care through the embedding package: a cluster randomised control trial and ethnographic study.

    Published in:
    BMC Primary Care, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s12875-024-02372-x
    By:
    • Davies, Melanie J;
    • Bodicoat, Danielle H;
    • Brennan, Alan;
    • Dixon, Simon;
    • Eborall, Helen;
    • Glab, Agnieszka;
    • Gray, Laura J;
    • Hadjiconstantinou, Michelle;
    • Huddlestone, Lisa;
    • Hudson, Nicky;
    • Keetharuth, Anju;
    • Khunti, Kamlesh;
    • Martin, Graham;
    • Northern, Alison;
    • Pritchard, Rebecca;
    • Schreder, Sally;
    • Speight, Jane;
    • Sturt, Jackie;
    • Turner, Jessica
    Publication type:
    Article
    3

    Increasing uptake of self-management education programmes for type 2 diabetes in primary care: the Embedding research programme including an RCT.

    Published in:
    Programme Grants for Applied Research (PGfAR), 2025, v. 13, n. 2, p. 1, doi. 10.3310/KWYF5914
    By:
    • Davies, Melanie J;
    • Agarwal, Shona;
    • Bodicoat, Danielle H;
    • Brennan, Alan;
    • Dixon, Simon;
    • Eborall, Helen;
    • Glab, Agnieszka;
    • Gray, Laura J;
    • Hadjiconstantinou, Michelle;
    • Huddlestone, Lisa;
    • Hudson, Nicky;
    • Keetharuth, Anju;
    • Khunti, Kamlesh;
    • Kristunas, Caroline;
    • Martin, Graham;
    • Northern, Alison;
    • Patterson, Mike;
    • Pollard, Daniel;
    • Pritchard, Rebecca;
    • Schreder, Sally
    Publication type:
    Article
    4
    5
    6

    The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1509, doi. 10.1111/dom.14721
    By:
    • Sargeant, Jack A.;
    • King, James A.;
    • Yates, Thomas;
    • Redman, Emma L.;
    • Bodicoat, Danielle H.;
    • Chatterjee, Sudesna;
    • Edwardson, Charlotte L.;
    • Gray, Laura J.;
    • Poulin, Benoit;
    • Waheed, Ghazala;
    • Waller, Helen L.;
    • Webb, David R.;
    • Willis, Scott A.;
    • Wilding, John P. H.;
    • Khunti, Kamlesh;
    • Stensel, David J.;
    • Davies, Melanie J.
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1409, doi. 10.1111/dom.14343
    By:
    • Ahmad, Ehtasham;
    • Waller, Helen L.;
    • Sargeant, Jack A.;
    • Webb, M'Balu A.;
    • Htike, Zin Zin;
    • McCann, Gerry P.;
    • Gulsin, Gaurav;
    • Khunti, Kamlesh;
    • Yates, Tom;
    • Henson, Joseph;
    • Davies, Melanie J.;
    • Webb, David R.
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20

    A randomized, open‐label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1187, doi. 10.1111/dom.14023
    By:
    • Webb, David R.;
    • Htike, Zin Zin;
    • Swarbrick, Daniel J.;
    • Brady, Emer M.;
    • Gray, Laura J.;
    • Biglands, John;
    • Gulsin, Gaurav S.;
    • Henson, Joseph;
    • Khunti, Kamlesh;
    • McCann, Gerry P.;
    • Waller, Helen L.;
    • Webb, M'Balu A.;
    • Sargeant, Jack A.;
    • Yates, Thomas;
    • Zaccardi, Francesco;
    • Davies, Melanie J.
    Publication type:
    Article
    21
    22
    23
    24
    25
    26

    Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1967, doi. 10.1111/dom.13791
    By:
    • Davies, Melanie J.;
    • Russell‐Jones, David;
    • Barber, Thomas M.;
    • Lavalle‐González, Fernando J.;
    • Galstyan, Gagik R.;
    • Zhu, Dalong;
    • Baxter, Mike;
    • Dessapt‐Baradez, Cecile;
    • McCrimmon, Rory J.
    Publication type:
    Article
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide ( iGlarLixi) vs insulin glargine and lixisenatide monocomponents

    Published in:
    Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1798, doi. 10.1111/dom.12980
    By:
    • Davies, Melanie J.;
    • Leiter, Lawrence A.;
    • Guerci, Bruno;
    • Grunberger, George;
    • Ampudia‐Blasco, F. Javier;
    • Yu, Christine;
    • Stager, William;
    • Niemoeller, Elisabeth;
    • Souhami, Elisabeth;
    • Rosenstock, Julio
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50